Table 4.
Cycles outcomes according to type of estrogen used.
| Transdermal group | Vaginal group | p | |
|---|---|---|---|
| Clinical pregnancy rate | |||
| • Per started cycle | 26.9 (32/119) | 24.6 (49/199) | 0.65 |
| • Per embryo transfer | 30.8 (32/104) | 26.9 (49/182) | 0.25 |
| Adverse pregnancy outcomes | |||
| • Biochemical pregnancy loss* | 9.4 (3/32) | 6.1 (3/49) | 0.58 |
| • Clinical pregnancy loss | 31.2(10/32) | 22.4 (11/49) | 0.38 |
| Live birth rate | |||
| • Per started cycle | 16 (19/119) | 17.6 (35/199) | 0.71 |
| • Per embryo transfer | 18.3 (19/104) | 19.2 (35/182) | 0.84 |
Data are expressed as percentage (n/total).
*biochemical pregnancy loss was defined after a first positive β-human Chorionic Gonadotropin (β-hCG) test (>25 mIU/mL), following by decreasing β-hCG levels without clinical pregnancy.